Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), maker of IZERVAY™ (avacincaptad pegol intravitreal solution), a C5 inhibitor for the treatment of geographic atrophy (GA ...

Atrial fibrillation recurrence after catheter ablation was not significantly linked to major adverse outcomes, regardless of ...

ECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion therapies for the treatment of liver disorders with significant unmet need, today announced ...

Explore how LC-MS technologies are transforming forensic and clinical toxicology by enabling comprehensive compound detection ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a target the company described as a high interest immune cell target in immunology ...

In recognition of Mental Health Month this May, outdoor lifestyle brand L.L.Bean will once again go "off the grid"??clearing ...

Instead of using AI as our intelligent virtual assistants, we are witnessing a generation of copy-paste machines that stop ...

Operating income in the first quarter 2025 was $1.4 million compared to $4.5 million in the prior year period. The decrease in operating income was attributable to the impact of lower sales volumes.

W hen done right, anime OPs are a thing of beauty. They can elevate a good series to greatness, ensuring that each episode ...

Ivanhoe Mines Ltd. ( OTCQX:IVPAF) Q1 2025 Earnings Conference Call May 1, 2025 10:30 AM ET Matthew Keevil - Director, IR and Corporate Communications Robert Friedland - Founder and Executive ...

Therapeutic options include incision and drainage in combination with antimicrobial therapy, which may be oral, topical or ... uncomplicated skin and skin structure infection (uSSSI), including ...